Aim 1: To show that specific endocrine related antibodies, known to be associated with endocrine gland failure, are a good predictive marker for development of endocrine related adverse events (ERAE) in patients with metastatic cancers treated with immune checkpoint regulators. To accomplish this aim, we will measure anti thyroid peroxidase antibody (Anti-TPO), anti thyroglobulin (anti-TG), thyroid stimulating immunoglobulin (TSI), anti glutamic acid decarboxylase (anti-GAD), and anti-adrenal antibodies before initiation of treatment and at the time of endocrine adverse event development. Aim 2: To determine how changes in levels of pituitary, thyroid, adrenal, and diabetes hormones predict development of ERAE. To accomplish this goal we will measure pituitary hormones, thyroid function tests, cortisol levels, and fasting blood sugar prior to treatment and at specified treatment intervals. Aim 3: To examine whether the specific type of immune checkpoint regulator used for treatment is associated with development of an ERAE.

• Cedars-Sinai Cancer at SOCC
• Cedars-Sinai Cancer at The Angeles Clinic and Research Institute